Hospital Admissions of Huntington’s Disease Patients in a Huntington’s Disease Centre Between 2011 and 2016: A Retrospective Analysis

Marina Peball, MD, PhD,1 Beatrice Heim, MD, PhD,1 Philipp Ellmerer, MD,1 Florian Frank, MD, PhD,1 Nadia Busin, MD,1 Matyas Galffy, MD,2 Atbin Djamshidian, MD, PhD,1,* and Klaus Seppi, MD1,*

Abstract: Background: Huntington’s Disease (HD) is a relentlessly progressive genetic neurodegenerative disorder with characteristic motor, psychiatric, and behavioral abnormalities that inevitably results in severe disability and death. Many patients have multiple hospital admissions during the disease course, but there is limited information which problems lead to hospitalization.

Objectives: To assess acute reasons for hospital admissions, discharge routes, and clinical characteristics of HD patients in a retrospective analysis.

Methods: We reviewed all medical records of patients with an established diagnosis of Huntington’s Disease and hospital admissions between 2011 and 2016 in our local hospital-based database.

Results: There were 135 hospital admissions in 53 HD patients during the review period, representing a median of two admissions per patient. Median duration of hospitalization was seven days. The most frequent reason for admission was a worsening of HD motor symptoms (n = 77, 57.0%) such as chorea, parkinsonism, gait problems, falls, and dysphagia. Psychiatric symptoms related to HD were the second most common reason for admission (n = 58, 43.0%). Infections (including aspiration pneumonia) and traumas/surgical procedures were only responsible for 6.7% and 5.9% of admissions, respectively. Emergency admissions were not common (42.2%), and the majority of patients were able to return to their previous residency upon discharge (85.2%, home or nursing home). Recurrent admissions were associated with worse motor function and functional capacity.

Conclusions: Worsening of motor and psychiatric symptoms associated with Huntington’s Disease were the most common reasons for hospital admissions. Therefore, our data highlight the importance of optimal symptom control in HD patients.

Huntington’s Disease (HD) is an incurable neurodegenerative disorder caused by autosomal dominantly inherited elongation of cytosine-adenine-guanine (CAG) repeats in the Huntington gene on chromosome 4p16.3. Patients present with motor, behavioral, and psychiatric abnormalities, whereas the latter may appear many years before age of onset as defined by the first...
occurrence of typical motor abnormalities.\textsuperscript{1,2} Progressive disability in HD patients is driven by the development of severe motor symptoms such as disabling chorea, bradykinesia, rigidity, dystonia, and dysphagia, as well as cognitive deficits, functional incapacity, and dependency in activities of daily living (ADLs).\textsuperscript{1,3} Falls, weight loss, and aspiration pneumonia are well-known consequences that may require attention of a specialist in an emergency setting.\textsuperscript{3} However, only very few studies have systematically assessed hospital utilization among the HD population.\textsuperscript{4–6}

In this retrospective analysis, we aimed to identify acute reasons for hospital admissions of adult HD patients treated at the Medical University of Innsbruck and its associated clinics as well as their baseline and clinical characteristics.

**Methods**

We performed a retrospective analysis of all symptomatic patients with a genetically confirmed diagnosis of HD that were hospitalized at the Medical University of Innsbruck and its associated clinics between the years 2011 and 2016. All these clinics are located in the center of Tyrol and belong to the Medical University of Innsbruck, the Psychiatric Hospital in Hall, and the District Hospital in Hall. The Medical University of Innsbruck is the largest clinic in our catchment area in western Austria and the neurological Department has a specialized HD center. Patients are also referred from eastern Austria, Bavaria, and South Tyrol. The Austrian health care system is predominantly financed publicly with inpatient stays mostly receiving funding from the provinces, national government, or local authorities. Other financial compensation comes from social insurance institutions (tax revenues), patients themselves, or private health insurances. The payment calculations are based on procedure-oriented diagnosis-related case groups (in German: “Lestungsorientierte Diagnosen-Fallgruppen,” LDF), i.e., an Austrian Diagnosis-related Group (DRG) system that considers medical procedures carried out, the respective International Classification of Diseases (ICD)-10 diagnosis, age of patients, and the hospital departments involved. Reimbursement for the duration of inpatient stay is capped.

For this retrospective study, data from our hospital database and the observational REGISTRY study of the European Huntington’s Disease Network (EHDN) were used to assess baseline and clinical characteristics of HD patients at admission.\textsuperscript{7} For further details on the REGISTRY study, please refer to the Supplementary material. The REGISTRY study and this retrospective data analysis were approved by the local ethics committee. Data collection, interviews, and examinations were carried out in accordance with the principles expressed in the Declaration of Helsinki.

**Procedures**

MP, NB, and MG extracted data from the medical records of all HD patients hospitalized in the respective time frame. Primary categories of interest were admission (emergency admission, high-priority admission) and discharge date and route, medical discipline, the primary symptoms on admission, the main procedures conducted, comorbidities and concomitant medication, and the final discharge diagnoses according to ICD Clinical Modification codes. Primary reasons for admission were classified into five categories: “infection (including aspiration pneumonia),” “worsening of neurological symptoms,” “worsening of psychiatric symptoms,” “surgery/traumatology,” and “other reasons.” For characterization of the patient’s motor symptom burden and functionality in ADLs at the time of admission, parts of the Unified Huntington’s Disease Rating Scale (UHDRS)\textsuperscript{8} were obtained from the REGISTRY study visit closest to the hospitalization (60.0%) or a respective UHDRS assessment (i.e., during an outpatient visit/ at admission, 40.0%). Disease stages of HD patients were determined as mild, moderate, or severe with respect to function in ADLs and the Total Functional Capacity (TFC) score.\textsuperscript{4,9,10} Comorbidities were evaluated using the Charlson Comorbidity Index (CCI), an index developed to measure overall chronic disease burden longitudinally and to predict survival.\textsuperscript{11}

**Statistical Analyses**

Categorical variables were given in number (n) and percent of the category. For quantitative measures the mean with its standard deviation and the median were calculated. Where appropriate, the interquartile range (IQR, P25–P75) was given. Integer data (length of stay, number of medications, CAG repeats) is presented as median (interquartile range and range). Descriptive analyses were performed on baseline, demographic, hospital admission, and discharge data as well as the UHDRS Total Motor Score (TMS), TMS—Chorea subscore, TFC, Functional Assessment (FA), and Independence Score (IS). The Chorea subscore was calculated as the sum of all items on chorea of the UHDRS TMS (face, bucco-oro-lingual region, trunk, both upper and lower extremities). Parametric and nonparametric tests were used for statistical analyses depending on the distribution and the scale type of the variables (see table legends). Spearman’s rank-order correlation (\(\rho\)) was used to test for any relationship between discharge route (home, nursing home placement, new nursing home placement) and total number of hospital admissions per person and any relationship between the latter and total number of visits to the neurological outpatient department in the time-period. The significance level was set at \(p \leq 0.05\) for all analyses. SPSS 25.0 for windows (SPSS Inc., IBM Corporation and other(s) 1989, 2017, Chicago, IL) was used to analyze data.

**Results**

In total, 161 patients with HD were treated in the specialized outpatient department between 2011 and 2016. This retrospective analysis included 53 patients (n = 36 female [67.9%], n = 52 Caucasian [98.1%]) with 135 hospital admissions over six years. Respectively, 32.9% of all HD patients seen in the outpatient department required a hospital admission. Per year, almost a
quarter of outpatients were admitted to the hospital (median 24.4%, Table S1). Interestingly, there was a weak but non-significant association between total number of hospital admissions per person and total number of visits to the neurological outpatient department ($r_1 = 0.246$, $P = 0.08$).

Table 1 shows demographic characteristics and clinical data of the 53 analyzed HD patients. The mean age of HD onset was 41.55 ± 10.92 (40.50) years in all patients. More than half of all patients ($n = 28$, 52.8%) had an advanced disease stage. The mean number of hospitalizations per patient was 2.55 ± 2.07 (2.00). Median duration of hospitalization was 7 days. Most HD patients had no HD-unrelated comorbid diseases at the time of hospitalization with a mean CCI of 0.56 ± 1.24 (0.00). Dementia was present in 20 patients (37.7%, with 53 hospital admissions, Table 1). All of them had an advanced disease stage. Patients with dementia had significantly more emergency admissions ($P < 0.01$). No significant association was found between dementia and different admission reasons. The median number of overall medications at admission was 5.00 and 6.00 at discharge with a statistically significant difference ($P < 0.01$).

Table 2 summarizes data of the 135 admissions and discharges. It must be noted that some patients had more than one primary reason for admission.

The most common reasons for admission were worsened neurological symptoms of HD ($n = 77$, 57.0%). Frequent complaints were a worsening of chorea, parkinsonism, gait problems with recurrent falls, or dysphagia ($n = 34$, 44.2%). Worsening of chorea was a major problem in 26 of 77 HD patients (33.8%) and worsening of akinetic-rigid symptoms in 35 of 77 patients (45.5%). A combination of choreatic and akinetic-rigid symptom deterioration was the reason for five of 77 neurologic admissions (6.5%). Recurrent falls ($>1$ in the previous year) were a major complaint in 25 hospital admissions (18.5%) in 14 patients (26.4%) including five injurious falls.

The other major reason for hospitalization of HD patients was worsening of psychiatric symptoms ($n = 58$, 43.0%) with depression (46.6%), agressive behavior (36.2%), agitation and irritability (41.4%), psychotic behavior with delusions (24.1%), or suicidal tendencies (Table 2). Five hospital admissions (3.7%, in four patients) were due to acute suicidal thoughts, none because of suicide attempts. In one patient this was due to an adverse reaction to tetrabenzine. In three demented patients, delirium led to admission to a psychiatric ward. According to the medical records, the psychiatric and behavioral problems improved upon discharge. Antipsychotics were documented as pre-existing medication in 73 (54.1%) of all admissions, antidepressants in 70 (51.9%), benzodiazepines in 62 (45.9%), amantadine in 43 (31.9%), tiapride in 5 (3.7%), tetrabenazine in 17 (12.6%), and levodopa in 10 (7.4%).

In 30 (51.7%) admissions to psychiatric wards, antipsychotics were the pre-existing medication, antidepressants in 24 (41.4%), benzodiazepines in 20 (34.5%), amantadine in 17 (29.3%), tiapride in 2 (3.5%), tetrabenazine in 8 (13.8%), and levodopa in 2 (3.5%) (Table S2).

Intriguingly, a worsening of both neurological and psychiatric symptoms was noted in 27 (20.0%) of the hospitalizations. Table 2 also summarizes further reasons for admission including admissions for infectious diseases, surgical/traumatological, and other reasons (table legend). Aspiration pneumonia was the reason for five hospital admissions (3.7%) and one death during inpatient stay (Table 2).

The most common relevant comorbidities in the patients hospitalized were urinary tract infections ($n = 53$, 39.3%) and gastrointestinal problems (i.e., esophageal with ulcer in a patient with nausea and vomiting) ($n = 5$, 3.7%).

All patients received physical, occupational, and speech therapy. The most frequent consultations during inpatient stays included neuropsychologists for cognitive assessment (11.1%), physicians from the Department of Hearing, Speech and Voice Disorders (9.6%), neurologists (5.9%) (i.e., if patients were not hospitalized at a neurological ward [51.1% of all admissions]), and psychiatrists (5.2%, Table S3). A detailed list of the main procedures conducted can be found in the Supplementary material and table.

In 67.4% of all hospitalizations, the primary discharge diagnosis was HD. A primary psychiatric discharge diagnosis was given in 13.3% and 3.7% either had a diagnosis of dementia or an infectious disease (e.g., aspiration pneumonia, Table 2). Two patients died during inpatient stay, one after a polytrauma from a biking accident and another due to aspiration pneumonia. Most hospitalizations (68.2%) resulted in a discharge back home or to a nursing home (20.0%). Four patients previously living with their families were admitted to a nursing home due to overall symptom worsening (Table 2; Mean age at admission: 57.98 years ± 13.78; median length of stay: 15 days). Two of these patients had been acutely admitted (psychosis, dementia/social indication) and a worsening of neurological symptoms (motor, cognitive) was the primary reason in three of these cases. There was a significant correlation between discharge route (home, nursing home placement, new nursing home placement) and number of total hospital admissions per person ($r_1 = 0.293$, $P < 0.01$). The four patients that were newly admitted to the nursing home had the highest number of hospital admissions respectively (6, 7, 11). In 5.9% of all admissions, a transfer to another hospital for further rehabilitation or therapy was necessary (Table 2).

HD patients who were admitted due to infections (including aspiration pneumonia) (64.44 years ± 9.55 [69.08]), or for surgeries/due to a trauma (68.26 years ± 15.66 [75.71]) were older than HD patients who were admitted due to a worsening of neurological (51.85 years ± 15.98 [52.42]) or psychiatric symptoms (50.93 years ± 12.18 [48.92]) or “other” reasons (47.72 years ± 17.38 [43.50], Table 3). Overall, surgical patients showed longer durations of inpatient stays (median: 17.50 days) than the other patient groups (neurological symptoms: 7.00 days; psychiatric symptoms: 7.00 days; “other”: 5.00 days; infections: 6.00 days). Emergency in-patient admissions mostly occurred in patients with a worsening of neurological symptoms ($n = 31$, 55.4%), infections (including aspiration pneumonia) ($n = 8$, 88.9%), and a surgery/trauma ($n = 6$, 75.0%). All 17 HD patients admitted due to infections (including aspiration pneumonia) or to a surgical ward/traumatology had a severe disease stage (Table 3).
**TABLE 1**  Demographic and clinical data of patients with Huntington’s disease

| Demographic data          |       |
|---------------------------|-------|
| Sex                       |       |
| Female                    | 36 (67.9%) |
| Male                      | 17 (32.1%) |
| Ethnicity                 |       |
| Caucasian                 | 52 (98.1%) |
| Other                     | 1 (1.9%) |
| Age of onset (in years)   |       |
| Female                    | 40.73 ± 9.99 (38.92)* |
| Male                      | 44.27 ± 13.93 (50.92)* |
| CAG repeat                |       |
| Short allele              | 18.00, P25–P75: 16.75–21.25, range: 11–38* |
| Longer allele             | 45.00, P25–P75: 43–47, range: 40–72 |
| First symptoms            |       |
| Motor                     | 29 (60.4%) |
| Psychiatric               | 11 (22.9%) |
| Cognitive decline         | 2 (4.2%) |
| Mixed                     | 6 (12.5%) |
| Handedness                |       |
| Right-handed              | 37 (90.2%) |
| Left-handed               | 2 (4.9%) |
| Both sides                | 2 (4.9%) |
| Marital status            |       |
| Married/in a relationship | 29 (54.7%) |
| Single/divorced/widowed   | 16 (30.2%) |
| Unknown                   | 8 (15.1%) |
| Working status            |       |
| Working (full-time / part-time) | 8 (3 / 5) (15.1%) |
| Unemployed (e.g., housewife) | 8 (15.1%) |
| Unemployed other reasons  | 2 (3.8%) |
| Retired due to age        | 7 (13.2%) |
| Retired due to HD         | 27 (50.9%) |
| Sick leave                | 1 (1.9%) |
| Family history            |       |
| Mother affected           | 19 (35.9%) |
| Father affected           | 22 (41.5%) |
| No affected parent or unknown | 12 (22.6%) |
| Mean age of onset in affected parent (in years) |       |
| Affected mother           | 46.00 ± 12.46 (40.00) |
| Affected father           | 46.00 ± 10.66 (40.00) |

*(Continues)*
Patients with more than two hospital admissions (i.e., recurrent admissions) had significantly higher score values of the TFC ($P = 0.01$), FA ($P = 0.01$), IS ($P = 0.02$), and the TMS ($P = 0.01$) at their first admission compared to patients who were only admitted once or twice between 2011 and 2016 (Table 4). Moreover, patients with recurrent admissions had significantly higher disease stages (mild: 5.6%, moderate: 22.2%, severe: 72.2%) when compared to patients with ≤2 admissions (mild: 34.2%, moderate: 22.9%, severe: 42.9%; $P = 0.05$, Table 4). There were no differences in sex, age, comorbidities (CCI), or disease duration in HD patients with ≤2 and >2 hospital admissions (Table 4).

**Discussion**

Here, we performed a retrospective analysis of 135 hospital admissions in 53 HD patients at the Medical University Innsbruck, Austria.

The most frequent reason for hospitalization was a worsening of motor symptoms of HD including chorea, parkinsonism, gait problems, falls, and dysphagia. Interestingly, in a total of 25 hospital admissions in 14 patients (26.4%), recurrent falls were a major complaint, with five of them being injurious falls requiring medical treatment. Indeed, recurrent falls are common in the HD population with a one-month incidence of 28.8%. Psychiatric symptoms related to HD
were the second most common reason for admission and included depression with five admissions due to suicidality, aggressive behavior, agitation and irritability, psychotic behavior with delusions, or delirium. The percentage of suicidal ideations in our cohort is consistent with previous studies. As expected for psychiatric admissions, the most common medication change was the introduction or change

**TABLE 2** Admission and Discharge characteristics

| Admission | Reasons for admission* (Total n = 135) |
|-----------|----------------------------------------|
|           | Worsening of neurologic symptoms*       |
|           | 77 (57.0%)                             |
|           | Worsening of psychiatric symptoms       |
|           | 58 (43.0%)                             |
|           | Other                                  |
|           | 13 (9.6%)                              |
|           | Infection (incl. Aspiration pneumonia)  |
|           | 9 (6.7%)                               |
|           | Surgery, traumatology                   |
|           | 8 (5.9%)                               |

| Admission source | |
|------------------|------------------|
| Emergency admission | 57 (42.2%)     |
| High-priority admission | 76 (56.3%) |
| Unknown | 2 (1.5%) (to psychiatry) |

| Discharge | Discharge diagnosis according to diagnostic code |
|-----------|-------------------------------------------------|
|           | from hospital information system (Total n = 135) |
|           | HD                                              |
|           | 91 (67.4%)                                      |
|           | Psychiatric diagnoses                           |
|           | 18 (13.3%)                                      |
|           | Other                                           |
|           | 16 (11.9%)                                      |
|           | Dementia (in HD or not specified)                |
|           | 5 (3.7%)                                         |
|           | Infection (incl. Aspiration pneumonia)          |
|           | 5 (3.7%)                                         |

| Discharge route/death during inpatient stay | |
|--------------------------------------------|------------------|
| Home                                       | 92 (68.2%)       |
| Nursing home/long-term care facility       | 27 (20.0%)       |
| New nursing home admission                | 4                |
| Other hospital                             | 8 (5.9%)         |
| Unknown                                    | 6 (4.4%)         |
| Death during hospitalization               | 2 (1.5%)         |

For categorical data the number and percent (%) are given.

*Some patients had more than one reason for admission.

Frequent complaints were a worsening of chorea (n = 26, 33.8%), parkinsonism (n = 35, 45.5%), a worsening of both chorea and parkinsonism (n = 5, 6.5%), gut problems with recurrent falls, or dysphagia (n = 34/77, 44.2%).

Worsening of psychiatric symptoms included depression (46.6%), aggressive behavior (36.2%), agitation and irritability (41.4%), psychotic behavior with delusions (24.1%), or suicidal tendencies.

“Other reasons” for admission (9.6%) included dental (desolate condition of the teeth and adaption of dental prosthesis, n = 2), and dermatologic (atopic dermatitis, n = 4 in 1 patient) treatment, admission due to retinal detachment (ophthalmologist, n = 3 in 1 patient), rehabilitation after a femoral neck fracture (n = 1), atrioventricular block III (internal medicine, n = 1), social reasons (n = 1), and withdrawal of analgesic medication in an HD patient with chronic mixed headache (n = 1) (Supplementary material).

A total of 6.7% of hospital admissions (n = 9) were due to infections: one phlegmon of the floor of the mouth (ear-nose-throat specialist, n = 1), aspiration pneumonia (n = 5), acute sigma diverticulitis and salpingitis (n = 1), and urinary tract infection (n = 2). Aspiration pneumonia was the reason for five hospital admissions (3.7%) and one death during inpatient stay.

Surgery and traumatology (n = 8, 5.9%) admissions comprised gastrointestinal obstructive symptoms (n = 1), revision after accidental removal of the percutaneous endoscopic gastrostomy (PEG) tube (n = 1), an operation of a cerebellar angle bridge tumor (n = 1), acute fractures of the humerus and femur (n = 1 each), a polytrauma (biking accident, n = 1), a head trauma with cerebral contusions and a nasal fracture (n = 1), as well as treatment of a chronic subdural hematoma (with an acute nasal fracture, n = 1). The latter five admissions were due to injurious falls.

Other primary discharge diagnoses (11.9%) included the diagnosis of a phlegmon of the base of the mouth (n = 1), a retinal detachment (n = 3), pyoderma and folliculitis (n = 1), atopic dermatitis (n = 3), traumatic subarachnoid hemorrhage (n = 2), a perforated diverticulitis of the colon sigmoidum (n = 1), a fracture of the femur (n = 1), multiple intracranial and cranial fractures after a trauma (n = 1), a fracture of the shoulder and shoulder girdle (n = 1), a newly diagnosed atrioventricular block (n = 1), and a neurological intervention for a tumor of the cerebello-pontine angle (n = 1).
### TABLE 3  Data of Huntington’s disease patients with different clinical presentation at admission

| Data at admission | Neurologic symptoms (n = 77) | Psychiatric symptoms (n = 58) | Other (n = 13) | Infection (including aspiration pneumonia) (n = 9) | Surgery, Traumatology (n = 8) |
|-------------------|-------------------------------|-------------------------------|---------------|-------------------------------------------------|-------------------------------|
| Age (in years)    | 52.60 ± 14.83 (53.25)         | 50.93 ± 12.18 (48.92)         | 47.72 ± 17.38 (43.50) | 64.44 ± 9.55 (60.08) | 68.26 ± 15.66 (75.71) |
| Length of stay (in days) | 7.00, P25–P75: 4–10, range: 1–42 | 7.00, P25–P75: 5–14.75, range: 1–348 | 5.00, P25–P75: 3–9.50, range: 1–71 | 6.00, P25–P75: 3.50–12, range: 3–49 | 17.50, P25–P75: 2.25–36.75, range: 1–52 |
| Disease duration (in years) | 11.65 ± 5.76 (11.71) | 11.14 ± 5.05 (11.17) | 9.51 ± 7.55 (8.58) | 16.42 ± 5.71 (14.88) | 16.78 ± 2.76 (17.75) |
| Females           | 59 (76.6%)                    | 32 (55.2%)                    | 8 (61.5%)      | 5 (55.6%)                                 | 6 (75.0%)                     |
| Admission         |                               |                               |               |                                               |                               |
| Emergency         | 15 (19.5%)                    | 31 (55.4%)                    | 4 (30.8%)      | 8 (88.9%)                                 | 6 (75.0%)                     |
| High-priority     | 62 (80.5%)                    | 25 (44.6%)                    | 9 (69.2%)      | 1 (11.1%)                                 | 2 (25.0%)                     |
| Disease stage     |                               |                               |               |                                               |                               |
| Mild              | 11 (14.3%)                    | 5 (8.6%)                      | 4 (30.8%)      | 0                                           | 0                             |
| Moderate          | 23 (29.9%)                    | 18 (31.0%)                    | 0             | 0                                           | 0                             |
| Severe            | 43 (55.8%)                    | 35 (60.3%)                    | 9 (69.2%)      | 9 (100%)                                  | 8 (100%)                      |
| Continuous data are presented as mean ± standard deviation (median). Integer data is presented as median (interquartile range and range). For categorical data the number is given. If the standard deviation provides a value below zero, the interquartile range is given. Abbreviation: P, percentile.

### TABLE 4  Clinical Characteristics of Huntington’s disease patients with ≤2/>2 admissions to the hospital

|                  | ≤2 admissions (n = 35) | >2 admissions (n = 18) | P-value a |
|------------------|------------------------|------------------------|-----------|
| Sex              | 0.89                   |                        |           |
| Male             | 11 (31.4%)             | 6 (33.3%)              |           |
| Female           | 24 (68.6%)             | 12 (66.7%)             |           |
| Age at first admission (years) | 52.09 ± 13.63 (51.25) | 49.69 ± 20.28 (48.66) | 0.61      |
| Disease duration at first admission (years) | 9.38 ± 5.71 (9.63) | 11.76 ± 5.57 (11.75) | 0.17      |
| Charlson comorbidity index | 0.46 ± 1.09 (0.00) (P25–P75: 0.00–1.00) | 0.33 ± 0.69 (0.00) (P25–P75: 0.00–0.25) | 0.66      |
| UHDRS TMS        | 37.48 ± 16.26 (37.00)  | 51.60 ± 12.75 (50.50)  | 0.01      |
| UHDRS TMS – Chorea subscore | 7.30 ± 5.03 (6.00)    | 9.10 ± 6.39 (11.50)    | 0.39      |
| TFC              | 8.26 ± 4.00 (9.00)     | 4.10 ± 2.42 (3.50)     | 0.01      |
| Disease stage    | 0.05                   |                        |           |
| Mild             | 12 (34.2%)             | 1 (5.6%)               |           |
| Moderate         | 8 (22.9%)              | 4 (22.2%)              |           |
| Severe           | 15 (42.9%)             | 13 (72.2%)             |           |
| FA               | 20.35 ± 8.02 (21.00)   | 13.60 ± 4.95 (14.00)   | 0.01      |
| IS               | 77.11 ± 16.61 (85.00)  | 62.50 ± 11.37 (57.50)  | 0.02      |

Categorical data are presented as n, %. Continuous data are given in mean ± standard deviation (median). If the standard deviation provides a value below zero, the interquartile range is given. Higher scores indicate better status of the patient in the TFC, the FA, and the IS. UHDRS TMS range: 0–124 points, Chorea subscore: 0–28 points, TFC: 0–13 points, FA: 0–25 points, IS: 5%–100%. a Unpaired t-test for normally distributed continuous variables (Chorea subscore, disease duration, Charlson Comorbidity Index, age at admission), Mann–Whitney U test for not normally distributed continuous variables (TMS, TFC, FA, IS). Chi-square test for categorical data. Abbreviations: n, number; UHDRS, Unified Huntington’ Disease Rating Scale; TMS, Total Motor Score; TFC, Total Functional Capacity; FA, Functional Assessment; IS, Independence Score.
An explanation for this may be that advanced HD is the most likely explanation of the discrepant results. There were only two patients. Of note, the number of admissions for hospitalization (3.7%) compared to other HD studies (42–44%). An explanation for this may be that advanced HD patients with pneumonia are more often referred to a local hospital. Moreover, our advanced HD patients often receive a palliative care plan for treatment at home or are placed in a long-term care facility.

Besides physical, occupational, and speech therapy, the most frequent consultations during inpatient stays were neuropsychologists, physicians from the Department of Hearing, Speech and Voice Disorders, neurologists (i.e., if patients were not hospitalized at a neurological ward), and psychiatrists. The number of long-term medications also changed significantly during hospitalization, both reflecting (motor) symptom burden and the need of therapeutic re-evaluation.

During the hospital stay, many of our patients were treated for well-known comorbidities and complications of HD such as gastrointestinal problems, urinary tract infections, dental complications, neurosurgical problems, or ophthalmological diseases. Most patients in our study were discharged with the primary diagnosis of HD, dementia associated with HD, or psychiatric symptoms associated with HD undermining the debilitating influence of the disease on the patient’s life.

By contrast to our findings, one American study found respiratory diseases (22.0%) and sepsis (11.2%), psychiatric symptoms (21.5%), and malnutrition, dehydration, and worsening of skin condition (15.5%) to be common reasons for hospital admissions in HD patients with similar age, but more advanced disease stages. Data in this study, however, were derived from the Healthcare Cost and Utilization Project (HCUP, Agency for Healthcare Research and Quality, AHRQ) which excludes federal, primary psychiatric, rehabilitation, or long-term care hospitals. The divergent reasons for hospital admissions compared to our study might be caused by differences of data acquisition and healthcare systems (USA versus Austria) as well as inclusion of more advanced HD patients in the American study. Of note, the number of admissions due to a trauma (5.7%) was comparable to our data.

Another more recent study assessed reasons for hospital admission in juvenile HD patients (here defined as people with HD aged ≤20 years) and found epilepsy, seizures, and convulsions to be most frequent (58.8%), followed by psychiatric symptoms (26.1%), and respiratory infections (15.9%). There were only two patients (3.8%) with pediatric HD (motor onset <18 years) in our cohort (CAG repeats on the longer allele: 70 and 72). By contrast to a pediatric onset of HD, seizures are an uncommon presentation in adult-onset HD. Therefore, a different clinical presentation of adult HD patients compared to patients with a younger age of onset is the most likely explanation of the discrepant results.

Most of our patients with worsening of neurologic or psychiatric symptoms could be discharged home, confirming the findings of an English study assessing HD patient’s discharge routes from a psychiatric ward. Fifty-three percent of all HD patients in our study were at an advanced disease stage, more common in the group with recurrent (>2) inpatient stays. Moreover, patients with recurrent admissions showed significantly higher dependency, functional impairment, and overall motor symptom burden (all P < 0.02). Sex, disease duration, age at first admission, and comorbidities were not associated with recurrent admissions. Thus, motor symptoms with subsequent limitations in daily functioning were not only the most prominent reason for HD patient’s hospital admission but also resulted in repeated inpatient stays. This emphasizes the need for therapeutic re-evaluation and organization of adequate assistance at home, which is regularly taken care of during inpatient stays at our clinics. The multidisciplinary treatment approach for motor impairment based on medication adjustments and exercise/intensive neurorehabilitation led to an improvement of motor symptoms during the hospital stay as reported by the patients and caregivers upon discharge from the neurologic and psychiatric wards. Different approaches have been evaluated in other countries: regular visits by a specialized HD nurse for example reduced the number and duration of hospital admissions in New Zealand significantly and remaining hospitalizations were more appropriate according to the authors.

Conclusion

This is one of only very few studies systematically assessing hospital admission in HD patients. Our data suggest that adult HD patients are predominantly admitted to the hospital due to a worsening of HD motor symptoms that result in limitations in daily functioning. The second most common reasons for admission in HD patients were psychiatric symptoms. Admissions due to traumas or infections (including aspiration pneumonia) as well as emergency admissions were less common, and discharge to the patient’s previous residency was possible in most cases. Our data highlight the importance of regular and careful neurological and psychiatric evaluation of HD patients, ideally in a specialized HD center, as well as optimal motor symptom control. In HD patients with debilitating symptoms, therapeutic re-evaluation may be necessary for treatment optimization with optimal monitoring of drug response and adverse events.

Acknowledgments

We want to thank all participants who voluntarily took part in the European Huntington’s Disease Network Registry Study.

Author Roles

1) Research project: A. Conception, B. Organization, C. Execution; 2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 3) Manuscript: A. Writing of the first draft, B. Review and Critique.

MP: 1B, 1C, 2A, 2B, 3A
Disclosures

Funding Sources and Conflicts of Interest: The European Huntington’s Disease Network Registry Study was funded by the CHDI. The study center received an unrestricted grant from AOP Orphan Pharmaceuticals AG for academic research in HD patients.

Financial Disclosures for the Previous 12 Months: MP, PE, NB, MG, and AD declare that there are no additional disclosures to report.

FF received honoraria from Novartis AG and Teva Pharmaceutical Industries Limited outside the submitted work. BH reports honoraria from Novartis AG and AOP Orphan Pharmaceuticals AG outside the submitted work. Klaus Seppi reports personal fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceuticals AG, Roche, Grünenthal, Stada, Licher Pharma, Biogen, BIAL and Abbvie, honoraria from the International Parkinson and Movement Disorders Society, research grants from FWF Austrian Science Fund, Michael J. Fox Foundation, and AOP Orphan Pharmaceuticals AG, outside the submitted work.

Ethical Compliance Statement: The REGISTRY study and this retrospective data analyses were approved by the ethics committee of the Medical University of Innsbruck. All patients or their legal representatives gave written informed consent prior to participate in the REGISTRY study. For the retrospective data analysis, informed patient consent was not necessary. On behalf of all co-authors, the first and corresponding author confirm that all authors have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

References

1. Bates GP, Doney R, Guella JF, et al. Huntington disease. Nat Rev Dis Primers 2015;1:15005.
2. McCollgan P, Tabrizi SJ. Huntington’s disease: a clinical review. Eur J Neurol 2018;25(1):24–34.
3. Nance MA. Comprehensive care in Huntington’s disease: a physician’s perspective. Brain Res Bull 2007;72(2–3):175–178.
4. Dubinsky RM. No going home for hospitalized Huntington’s disease patients. Mov Disord 2005;20(10):1516–1522.
5. Mendzhabal A, Ngo Vu AT, Thibault D, Gonzalez-Alegre P, Willis A. Hospitalizations of children with Huntington’s disease in the United States. Mov Disord Clin Pract 2017;4(2):682–688.
6. Vassdev A, Palmer T, Thomas A, Burn D, Barker W. Factors predicting discharge of Huntington’s disease patients from a neuropsychiatry unit. Int J Occup Med Environ Health 2010;22(3):489–492.
7. Orth M, European Huntington’s Disease Network, Handleby OJ, et al. Observing Huntington’s disease: the European Huntington’s disease network’s REGISTRY. J Neurol Neurosurg Psychiatry 2011;82(12):1409–1412.
8. Huntington Study Group. Unified Huntington’s disease rating scale: reliability and consistency. Mov Disord 1996;11(2):136–142.
9. Shoulson I. Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981;31(10):1333–1335.
10. Johnson AC, Pulshein JS, Lovecky D, Tarapata K. Understanding behavior in Huntington’s disease: a guide for professionals. NY, USA: Huntington’s Disease Society of America; 2014:19.
11. Charlton ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373–383.
12. Kalkers K, Schols J, van Zwart EW, Roos RAC. Falls, fear of falling, and preventive measures in Huntington’s disease: the perspectives of individuals with Huntington’s disease and caregivers in long-term care. J Huntington Dis 2021;10(4):493–503.
13. Kesler RC, Berglund P, Borges G, Nock M, Wang PS. Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990–1992 to 2001–2003. JAMA. 2005;293(20):2487. http://dx.doi.org/10.1001/jama.293.20.2487.
14. Sorensen SA, Fenger K. Causes of death in patients with Huntington’s disease and in unaffected first degree relatives. J Med Genet 1992;29(12):911–914.
15. Lanska DJ, Levine L, Lanska MJ, Schoenberg BS. Huntington’s disease mortality in the United States. Neurology 1988;38(5):769–772.
16. Heemskerk AW, Roos RAA. Aspiration pneumonia and death in Huntington’s disease. J Neurosurg 2012;117(2):1607–1611.
17. Solberg OK, Filkuvkova P, Frich JC, Feragen KJB. Age at death and causes of death in patients with Huntington disease in norway in 1986–2015. J Huntington Dis 2021;8(3):1–17.
18. Ziaulka D, Witkowski G, Pach EA, Lesniszczak M, Mazur-Michalek I, Isalan M, Mielcarek M. Prevalence of non-psychiatric comorbidities in pre-symptomatic and symptomatic Huntington’s disease gene carriers in Poland. Front Med (Lausanne) 2020;7:779.
19. Andrich JE, Wobben M, Klotz P, Goetze O, Saft C. Upper gastrointestinal findings in Huntington’s disease: patients suffer but do not complain. J Neurol Neurosurg Psychiatry 2005;76(11):1607–1611.
20. Vicars BG, Liu AB, Holt S, Jayadev S, Bird T, Yang CC. High frequency of concomitant bladder, bowel, and sexual symptoms in Huntington’s disease: a self-reported questionnaire study. J Pers Med 2021;11(8).
21. Jackowski J, Andrich J, Kappeler H, Zollner A, Johren P, Muller T. Implant-supported denture in a patient with Huntington’s disease: interdisciplinary aspects. Spec Care Dentist 2001;21(1):15–20.
22. Saft C, Andrich JE, Muller T, Becker J, Jackowski J. Oral and dental health in Huntington’s disease—an observational study. BMC Neurol 2013;13:114.
23. Pechlivanis I, Andrich J, Scholz M, Harders A, Saft C, Schneider K. Chronic subdural haematoma in patients with Huntington’s disease: an observational study. J Neural Transm (Vienna) 2013;13:114.
24. Quarrell OWJ, Mielcarek M. Prevalence of non-psychiatric comorbidities in pre-symptomatic and symptomatic Huntington’s disease: a guide for professionals. J Huntingtons Dis 2018;7(1):77–86.
25. Achenbach J, Thiels C, Lucke T, Saft C. Data from ENROLL-HD: is the prevalence of non-psychiatric comorbidities in Huntington’s disease overestimated? Mov Disord 2019;34(4):584–585.
26. Achenbach J, Saft C. Data from ENROLL-HD: is the prevalence of juvenile and pediatric Huntington’s disease underestimated? Parkinson Relat Disord 2021;88:1–2.
27. Quarrell OWJ, Mielcarek M, Paulsen JS, Smith JA, Spec Care Dentist. 2013;33(3):267–276.
28. Achenbach J, Thiels C, Lucke T, Saft C. Clinical manifestation of juvenile and pediatric HD patients: a retrospective case series. Brain Sci 2020; 10(6):41–57.
29. Bourke D, Finucane G, Dysart J, Redburn R. The appointment of a Huntington’s disease nurse specialist has reduced admission rate and improved admission quality. J Huntington Dis 2012;1(1):27–30.

Supporting Information

Supporting information may be found in the online version of this article.

Appendix S1 Supporting information.